Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Transfusion ; 45(6): 911-9, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15934989

RESUMO

BACKGROUND: Several strategies are being developed to reduce the risk of pathogen transmission associated with platelet (PLT) transfusion. STUDY DESIGN AND METHODS: The impact of a new technology for pathogen reduction based on riboflavin plus illumination (Mirasol PRT, Navigant Biotechnologies, Inc.) at 6.2 and 12.3 J per mL on functional and biochemical characteristics of PLTs was evaluated. PLT concentrates (PCs) obtained by apheresis were treated with Mirasol PRT and stored at 22 degrees C. Modifications in major PLT glycoproteins (GPIbalpha, GPIV, and GPIIb-IIIa), adhesive ligands (von Willebrand factor [VWF], fibrinogen [Fg], and fibronectin), activation antigens (P-selectin and LIMP), and apoptotic markers (annexin V binding and factor [F]Va) were analyzed by flow cytometry. Adhesive and cohesive PLT functions were evaluated with well-established perfusion models. Studies were performed on the preparation day (Day 0) and during PCs storage (Days 3 and 5). RESULTS: Levels of glycoproteins remained stable during storage in PCs treated with 6.2 J per mL pathogen reduction technology (PRT) and similar to those observed in nontreated PCs. When 12.3 J per mL PRT was applied, however, levels of GPIbalpha moderately decreased on Days 3 and 5. VWF, Fg, and FVa were not modified in their expression levels, either by treatment or by storage period. Fibronectin appeared more elevated in all PRT samples. A progressive increase in P-selectin and LIMP expression and in annexin V binding was observed during storage of PRT-treated PCs. Functional studies indicated that 6.2 J per mL Mirasol PRT-treated PLTs preserved adhesive and cohesive functions to levels compatible with those observed in the respective control PCs. CONCLUSION: PLT function was well preserved in PCs treated with 6.2 J per mL Mirasol PRT and stored for 5 days.


Assuntos
Plaquetas , Plaquetas/efeitos dos fármacos , Plaquetas/efeitos da radiação , Preservação de Sangue , Riboflavina/farmacologia , Raios Ultravioleta , Anexina A5/análise , Anexina A5/efeitos dos fármacos , Anexina A5/efeitos da radiação , Antígenos CD/análise , Antígenos CD/efeitos dos fármacos , Antígenos CD/efeitos da radiação , Plaquetas/química , Plaquetas/citologia , Plaquetas/fisiologia , Fibrinogênio/análise , Fibrinogênio/efeitos dos fármacos , Fibrinogênio/efeitos da radiação , Fibronectinas/análise , Fibronectinas/efeitos dos fármacos , Fibronectinas/efeitos da radiação , Citometria de Fluxo , Humanos , Proteínas de Membrana Lisossomal , Selectina-P/análise , Selectina-P/efeitos dos fármacos , Selectina-P/efeitos da radiação , Ativação Plaquetária/efeitos dos fármacos , Ativação Plaquetária/efeitos da radiação , Adesividade Plaquetária/efeitos dos fármacos , Adesividade Plaquetária/efeitos da radiação , Contagem de Plaquetas , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/análise , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/efeitos dos fármacos , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/efeitos da radiação , Complexo Glicoproteico GPIb-IX de Plaquetas/análise , Complexo Glicoproteico GPIb-IX de Plaquetas/efeitos dos fármacos , Complexo Glicoproteico GPIb-IX de Plaquetas/efeitos da radiação , Glicoproteína IIb da Membrana de Plaquetas/análise , Glicoproteína IIb da Membrana de Plaquetas/efeitos dos fármacos , Glicoproteína IIb da Membrana de Plaquetas/efeitos da radiação , Transfusão de Plaquetas , Plaquetoferese , Temperatura , Fatores de Tempo , Fator de von Willebrand/análise , Fator de von Willebrand/efeitos dos fármacos , Fator de von Willebrand/efeitos da radiação
2.
J Thromb Haemost ; 1(11): 2411-8, 2003 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-14629477

RESUMO

BACKGROUND: Pigs have been widely used as animal models to study hemostasis. However, there are significant differences when comparing the hemostatic behavior of pig and human platelets. OBJECTIVE: To investigate signaling through tyrosine-phosphorylation of proteins in pig platelets after activation in suspension or by adhesion under flow conditions, in comparison with human platelets. METHODS: Activation of platelet suspensions was performed with thrombin (T; 0.1 and 1 U mL(-1)) and type I collagen (Col-I; 20 microg mL(-1)), at two different time points (30 and 90 s). Activation by adhesion was carried out on Col-I-coated coverslips, using citrated whole blood samples perfused through a parallel-plate chamber. RESULTS AND CONCLUSIONS: Significant differences between pig and human platelets were detected before and after activation. Activation of pig platelets required higher concentrations of thrombin, as well as increased activation times, to achieve similar levels of tyrosine phosphorylation. Proteins p160, p140, p85 and pp62, present in human platelets, were not detected in profiles corresponding to activated pig platelets. A protein of 70 kDa appeared only in pig platelet profiles, p55 was highly phosphorylated, and the phosphorylation levels of some proteins were significantly different from those found in human platelet profiles. In profiles corresponding to adhered pig platelets, p85 and p62 were absent, and p115 appeared highly phosphorylated. As observed in suspension studies, p70 and p55 appeared specifically in adhered pig platelets. Our study shows that the phosphotyrosine proteins involved in the activation of pig platelets are significantly different from those observed in activated human platelets. These findings may help to explain the differing adhesive and cohesive properties of platelets from both species, which should be considered when extrapolating results.


Assuntos
Plaquetas/metabolismo , Fosfoproteínas/metabolismo , Suínos/sangue , Tirosina/metabolismo , Animais , Plaquetas/química , Humanos , Cinética , Fosforilação , Ativação Plaquetária , Transdução de Sinais , Trombina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...